(Q43508140)

24 November 2017

title

Vigabatrin-associated visual field defects in children (English)

1 reference

24 November 2017

Russell-Eggitt IM

1

1 reference

24 November 2017

Mackey DA

2

1 reference

24 November 2017

Taylor DS

3

1 reference

24 November 2017

Timms C

4

1 reference

24 November 2017

Walker JW

5

1 reference

24 November 2017

publication date

1 June 2000

1 reference

24 November 2017

1 reference

24 November 2017

volume

14 ( Pt 3A)

1 reference

24 November 2017

page(s)

334-339

1 reference

https://scigraph.springernature.com/pub.10.1038/eye.2000.83

24 November 2017

exact match

0 references

cites work

Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in?

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Newer anticonvulsant drugs: role of pharmacology, drug interactions and adverse reactions in drug choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Chronic toxicity studies with vigabatrin, a GABA-transaminase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Severe persistent visual field constriction associated with vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Severe persistent visual field constriction associated with vigabatrin. Chronic refractory epilepsy may have role in causing these unusual lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Symptomatic and asymptomatic visual loss in patients taking vigabatrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Visual field defect associated with vigabatrin: observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Guideline may help in prescribing vigabatrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

Infantile spasms and vigabatrin. Study will compare effects of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Study is needed of visual field defects associated with any long term antiepileptic drug

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Reversibility of vigabratin-induced visual-field defect

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Vigabatrin-associated retinal cone system dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Severe visual-field constriction and side-effects of GABA-mimetic antiepileptic agents

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Second study supports results of Whitehall study after retirement

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.83

7 January 2021

Identifiers

DOI

10.1038/EYE.2000.83

1 reference

Dimensions Publication ID

24 November 2017

1040490110

0 references

1 reference